Eupraxia Pharmaceuticals Inc. announced positive results from a new analysis of its Phase 1b/2a RESOLVE trial for EP-104GI. The study targeted Eosinophilic Esophagitis (EoE), showing significant reductions in both painful swallowing (odynophagia) and difficulty swallowing (dysphagia).
Symptom relief was sustained for up to 52 weeks after treatment. In higher-dose cohorts, the percentage of patients reporting severe odynophagia dropped from 23% at baseline to zero at both the 24 and 52-week marks. The treatment was well-tolerated with no serious adverse events related to the medication or procedure reported.
These findings are significant as painful swallowing is a key component of patient-reported outcome questionnaires used in pivotal EoE clinical trials. Eupraxia expects to release interim data from its placebo-controlled Phase 2b RESOLVE study in the fourth quarter of 2026.